Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-label, Controlled, Multicentre, Phase 2 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)

NCT06075706 is registered in ClinicalTrials.gov with medac GmbH as lead sponsor.

NCT NCT06075706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-label, Controlled, Multicentre, Phase 2 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)
Lead sponsor
medac GmbH
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 13, 2023
Completion date
June 30, 2031
Enrollment
49 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

steroid-refractory acute graft-versus-host disease